Drugs / UI059
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06393881 | Jul → Sep 2024 | digestive system disorder | Korea United Pharm. Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT06141577 | Oct → Nov 2023 | gastroesophageal reflux disease | Korea United Pharm. Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UI059 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06141577 ↗ |
| Route | Oral | “after oral administration of UI059 and UIC202201 in healthy adult volunteers” NCT06141577 ↗ |